Psychiatry & Neurology Doctors in Cortlandt Manor, NY Accepting Medicare

4 Psychiatry & Neurology doctors found. Showing 1 - 4

Dr. Douglas Sankar, MD Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 1978 Crompond Rd, Cortlandt Manor, NY 10567 Phone: 914-293-8600    Fax: 914-293-8606

Silviu M Burcescu, MD Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 7 Croton Ave, Suite 100, Cortlandt Manor, NY 10567 Phone: 914-962-5800    Fax: 815-301-5504

Dr. Lyerka Balenovic Drezga, M.D. Psychiatry & Neurology - Child & Adolescent Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 341 Furance Dock Rd, Unit 54, Cortlandt Manor, NY 10567 Phone: 914-739-5825

Ann E Hanley, MD Psychiatry & Neurology - Neurology Medicare: Medicare Enrolled Practice Location: 1978 Crompond Road, The Westchester Medical Practice Pc, Cortlandt Manor, NY 10567 Phone: 914-293-8600    Fax: 914-293-8606

News Archive

Study: Low SES is linked to high risk of depression in patients with RA

Physical and Mental Health Disparities Found in Those with Low Socioeconomic Position. A recent study confirmed that low socioeconomic status is associated with higher risk of depressive symptoms in patients with rheumatoid arthritis.

UT Dallas students and faculty win three ASHA competitive awards

UT Dallas students and faculty have won three competitive awards from the American Speech Language and Hearing Association (ASHA), which will present the prizes at its annual conference this week in San Diego.

Atypical antipsychotic drugs slightly increase risk for death when used in people with dementia

Atypical antipsychotic drugs seem to confer a small increased risk for death when used in people with dementia, concludes a team of researchers from the Keck School of Medicine of the University of Southern California in a meta-analysis of 15 clinical trials published in the October 19 issue of the JAMA: The Journal of the American Medical Association.

The effect of Raloxifene treatment in postmenopausal women with chronic kidney disease

The osteoporosis drug raloxifene increases bone mineral density and reduces the risk of vertebral fractures among postmenopausal women with mild to moderate chronic kidney disease (CKD), according to a study appearing in the July 2008 issue of the Journal of the American Society Nephrology.

Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

Regeneron Pharmaceuticals, Inc. announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol therapy, ARCALYST (rilonacept) met the primary and all secondary study endpoints. The primary endpoint was the number of gout flares per patient over the 16-week treatment period.

Read more Medical News

› Verified 9 days ago